Anavex Life Sciences (AVXL) Stock Price
AVXLStock
$3.56−67.37%52W
Market Cap$330.00M
P/E—
PEG Ratio—
Div yield—
Beta1.16
AVXL Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-34.27%
Price vs S&P 500 (4W)17.96%
VGM Score38.07
AVXL Earnings Surprise History
Q1 25-0.13est. -0.15
Q2 25-0.16est. -0.14
Q3 25-0.11est. -0.15
Q4 25-0.06est. -0.11
Q1 26-0.06est. -0.07
AVXL Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.13
4.14
4.14
4.14
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AVXLAnavex Life Sciences | — | — | D | $3.56 |
| AMGNAmgen Inc | C | C | B | $442.24 |
| GILDGilead Sciences Inc | C | B | B | $148.77 |
| MRNAModerna, Inc. Common Stock | D | C | A | $158.83 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1019.49 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $211.38 |
| BIIBBiogen Inc. Common Stock | C | D | B | $220.77 |
| BNTXBioNTech SE American Depositary Share | C | C | B | $114.05 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $153.37 |
| EXELExelixis Inc | C | B | B | $56.72 |
| HALOHalozyme Therapeutics, Inc. | C | B | A | $109.32 |
About Anavex Life Sciences
Anavex Life Sciences is a clinical-stage biopharmaceutical company developing precision medicine treatments for central nervous system disorders with high unmet need. The company uses genomic biomarker analysis to advance programs targeting Alzheimer's disease, Parkinson's disease, schizophrenia, and rare neurological conditions including Rett syndrome. Its lead candidates, ANAVEX 2-73 and ANAVEX 3-71, are in clinical development, with additional compounds in earlier-stage programs.